Physician profile
Steven Mark Shrum
NPI 1669430286
$1,368.55
in general payments reported to CMS, 2019-2025
19 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $197 · 2021: $264 · 2022: $174 · 2023: $261 · 2024: $178 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $340.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $212.25 | 2020-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $147.04 | 2021-2023 | Qulipta |
| Merck Sharp & Dohme LLC | $132.15 | 2019-2021 | |
| Pfizer INC. | $102.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $91.39 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $70.85 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $64.90 | 2019-2024 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $30.18 | 2021-2023 | Spravato |
| Supernus Pharmaceuticals, INC. | $28.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $27.85 | 2021 | |
| Allergan, INC. | $24.51 | 2020 | |
| Sanofi Pasteur INC. | $16.45 | 2023 | |
| Sunovion Pharmaceuticals INC. | $15.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.12 | 2024 | Airsupra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $13.72 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.09 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.